Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2017-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2017
2017-05-15 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the offering, company business, risk factors, management, financial statements, and other disclosures typical of a registration prospectus. This is not an annual report, earnings release, or any other type of financial or governance report. It is a capital markets filing related to the company's initial or subsequent public offering of securities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not a brief announcement or certification.
2017-05-12 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2017. It reports the entry into a material definitive agreement involving convertible promissory notes and financing arrangements. The content focuses on financing activities, including issuance of convertible notes and related agreements. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other types of filings. The primary subject is clearly related to financing updates and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4587 characters, which is consistent with a detailed 8-K filing on financing events rather than a brief announcement or a full report.
2017-05-11 English
Regulatory Filings 2017
Regulatory Filings
2017-04-12 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from Citius Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural acknowledgments related to the registration statement's effectiveness. There is no financial data, report content, or detailed disclosures typical of an actual registration statement or financial report. The document is a formal regulatory communication related to the filing process, not the filing itself. Given the short length (2246 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) rather than a full registration statement or other report type.
2017-04-07 English
FORM S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A registration statement filed with the SEC, dated April 4, 2017, for Citius Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the offering, company overview, business strategy, risk factors, and financial statements. This type of filing is a capital markets document related to fundraising and securities registration, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2017-04-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.